抗血管内皮増殖因子治療薬の世界市場レポート 2025年

抗血管内皮増殖因子治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR2.3％で134億9,000万米ドルに成長します。予測期間における成長は、人口の高齢化と眼疾患、網膜疾患における用途の拡大、次世代治療薬の開発、早期介入の重視の高まり、世界の健康への取り組み、治療へのアクセスなどに起因すると考えられます。予測期間における主な動向としては、がん治療における利用拡大、眼科領域における併用療法の重視、バイオシミラー医薬品の探索、耐性メカニズムの調査、画像技術との統合などが挙げられます。

眼科疾患の罹患率の増加は、抗血管内皮増殖因子治療薬市場の拡大を促進すると予想されます。眼科疾患の有病率は、特定の集団における特定の眼疾患や障害の発生を意味します。抗血管内皮増殖因子（VEGF）治療薬は、湿性加齢黄斑変性症（AMD）、糖尿病網膜症、網膜静脈閉塞症などの有病眼疾患に対抗する上で極めて重要な役割を果たしています。2022年10月現在、世界保健機関（WHO）の報告によると、世界の視力障害は約22億人に影響を及ぼしており、加齢黄斑変性800万人、糖尿病網膜症約390万人など、特定の症状が10億人に影響を及ぼしています。この普及率が抗血管内皮増殖因子治療薬市場の成長の原動力となっています。

ヘルスケア・インフラへの投資の増加は、今後の抗血管内皮増殖因子（VEGF）治療薬市場の成長を促進すると予想されています。この支出には、病院、診療所、医療機器、情報システムなどのヘルスケア施設や資産の開発、維持、強化に割り当てられる財源が含まれます。このような投資は、治療へのアクセスを改善し、新技術の採用を促進し、認知度を高めて早期発見を促進し、研究開発における官民連携を促進することにより、抗VEGF治療薬市場において重要な役割を果たしています。例えば、2024年5月、英国の政府機関である国家統計局は、2022年から2023年にかけて総ヘルスケア支出が名目ベースで5.6%増加したのに対し、2022年の伸びはわずか0.9%であったと報告しています。このように、ヘルスケア・インフラへの投資の増加が抗VEGF治療薬市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界抗血管内皮増殖因子治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の抗血管内皮増殖因子治療薬市場：成長率分析
• 世界の抗血管内皮増殖因子治療薬市場の実績：規模と成長, 2019-2024
• 世界の抗血管内皮増殖因子治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界抗血管内皮増殖因子治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗血管内皮増殖因子治療薬市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アイレア
• ルセンティス
• ベオヴ
• 世界の抗血管内皮増殖因子治療薬市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 黄斑浮腫
• 糖尿病網膜症
• 網膜静脈閉塞症
• 加齢黄斑変性症
• 世界の抗血管内皮増殖因子治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 腫瘍学センター
• その他のエンドユーザー
• 世界の抗血管内皮増殖因子治療薬市場、Eyleaのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 適応症
• 剤形
• 世界の抗血管内皮増殖因子治療薬市場、ルセンティスのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 適応症
• 剤形
• 世界の抗血管内皮増殖因子治療薬市場、Beovuのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 適応症
• 剤形

第7章 地域別・国別分析

• 世界の抗血管内皮増殖因子治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗血管内皮増殖因子治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗血管内皮増殖因子治療薬市場：競合情勢
• 抗血管内皮増殖因子治療薬市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Coherus BioSciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bausch Health Companies Inc.
• Viatris Inc.
• Xbrane Biopharma AB
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• Genentech Inc
• Allergan Inc.
• Novartis AG
• kyowa Kirin Co. Ltd.
• Amgen Inc.
• AstraZeneca plc
• Merck & Co. Inc.
• Johnson & Johnson Private Limited
• Sanofi S.A.
• AbbVie Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗血管内皮増殖因子治療薬市場2029：新たな機会を提供する国
• 抗血管内皮増殖因子治療薬市場2029：新たな機会を提供するセグメント
• 抗血管内皮増殖因子治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anti-vascular endothelial growth factor (VEGF) therapeutics constitute a class of medications designed to impede the growth of blood vessels, particularly prevalent in the treatment of ophthalmic conditions. These drugs function by inhibiting vascular endothelial growth factors and find widespread application in the therapeutic intervention of various tumors and age-related macular degeneration.

The primary products within the category of anti-vascular endothelial growth factor therapeutics include Eylea, Lucentis, and Beovu. Eylea is a medication specifically indicated for the treatment of certain eye conditions, such as macular degeneration and diabetic retinopathy. Serving as an anti-VEGF therapeutic agent, Eylea effectively hinders the abnormal growth of blood vessels in the eye, particularly associated with retinal diseases. The utilization of anti-vascular endothelial growth factor therapeutics extends to the treatment of macular edema, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration. These therapeutics are commonly employed by hospitals, clinics, oncology centers, and other healthcare facilities in addressing a range of ophthalmic disorders.

The anti-vascular endothelial growth factor therapeutics market research report is one of a series of new reports from The Business Research Company that provides anti-vascular endothelial growth factor therapeutics market statistics, including anti-vascular endothelial growth factor therapeutics industry global market size, regional shares, competitors with a anti-vascular endothelial growth factor therapeutics market share, detailed anti-vascular endothelial growth factor therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the anti-vascular endothelial growth factor therapeutics industry. This anti-vascular endothelial growth factor therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-vascular endothelial growth factor therapeutics market size has grown marginally in recent years. It will grow from$12.2 billion in 2024 to $12.31 billion in 2025 at a compound annual growth rate (CAGR) of 1.0%. The growth in the historic period can be attributed to rise in age-related macular degeneration, increased incidence of diabetic retinopathy, advancements in retinal disease diagnosis, clinical success and efficacy, shift to outpatient treatment

The anti-vascular endothelial growth factor therapeutics market size is expected to see steady growth in the next few years. It will grow to $13.49 billion in 2029 at a compound annual growth rate (CAGR) of 2.3%. The growth in the forecast period can be attributed to aging population and ocular diseases, expanding applications in retinal disorders, development of next-generation therapeutics, increasing emphasis on early intervention, global health initiatives and access to treatment. Major trends in the forecast period include increasing utilization in cancer treatment, focus on combination therapies in ophthalmology, exploration of biosimilar versions, research on resistance mechanisms, integration with imaging technologies.

The rise in the incidence of ophthalmic diseases is anticipated to drive the expansion of the anti-vascular endothelial growth factor therapeutics market. Ophthalmic disease prevalence signifies the occurrence of specific eye conditions or disorders within a given population. Anti-vascular endothelial growth factor (VEGF) therapeutics play a pivotal role in combating prevalent eye ailments such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. As of October 2022, the World Health Organization reported global vision impairment affecting approximately 2.2 billion people, with specific conditions impacting 1 billion individuals, including 8 million with age-related macular degeneration and approximately 3.9 million experiencing diabetic retinopathy. This prevalence underscores the driving force behind the growth of the anti-vascular endothelial growth factor therapeutics market.

Increasing investment in healthcare infrastructure is anticipated to drive the growth of the anti-vascular endothelial growth factor (VEGF) therapeutics market in the future. This expenditure encompasses the financial resources allocated to developing, maintaining, and enhancing healthcare facilities and assets, including hospitals, clinics, medical equipment, and information systems. Such investments play a vital role in the anti-VEGF therapeutics market by improving treatment accessibility, facilitating the adoption of new technologies, raising awareness and promoting early detection, and encouraging public-private partnerships in research and development. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a mere 0.9% growth in 2022. Thus, the rising investment in healthcare infrastructure is propelling the growth of the anti-VEGF therapeutics market.

Advancements in therapeutic approaches represent a prominent trend driving growth within the anti-vascular endothelial growth factor therapeutics market. Companies active in this domain are embracing cutting-edge therapeutic methodologies to fortify their market presence. For instance, in May 2022, Ashvattha Therapeutics Inc., a US-based biopharmaceutical firm, disclosed phase 1 safety data for healthy subjects concerning their subcutaneous anti-VEGF wet AMD and DME candidates, namely D-4517.2 therapy. D-4517.2 is an innovative therapy designed to target unaddressed needs in DME conditions. Notably, this therapy is designed for self-administration through an autoinjector, allowing patients the convenience of self-administering the medication once monthly from the comfort of their homes.

Major players within the anti-vascular endothelial growth factor therapeutics sphere are strategically aligning through partnerships to propel the development and commercialization of VEGF inhibitors, thereby optimizing market gains. Such collaborations play a pivotal role in steering research and development, accessing novel technologies and candidates, expanding market penetration, and facilitating the commercial launch of VEGF inhibitors. For example, in June 2022, Biogen Inc., a US-based biotech enterprise, in collaboration with Samsung Bioepis, a South Korea-based biopharmaceutical company, introduced BYOOVIZ (ranibizumab-nuna) in the United States. BYOOVIZ stands as the premier FDA-endorsed ophthalmology biosimilar, specifically tailored for treating neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization. Functioning as a vascular endothelial growth factor (VEGF) inhibitor, BYOOVIZ marks the inaugural biosimilar launch in the U.S. within the Biogen and Samsung Bioepis partnership. Under this collaboration, Samsung Bioepis is accountable for development, regulatory processes, and product manufacture, while Biogen shoulders the responsibility for commercialization.

In August 2022, Coherus BioSciences Inc., a US-based commercial-stage biopharmaceutical company, acquired the commercialization rights to FYB203 from Klinge Biopharma GmbH for an undisclosed amount. This acquisition significantly enhances Coherus's portfolio of ophthalmology products, particularly within the anti-vascular endothelial growth factor (anti-VEGF) segment. Klinge Biopharma GmbH, based in Germany, specializes in pharmaceutical manufacturing, and this deal allows Coherus to strengthen its position in the growing market for therapies targeting conditions such as age-related macular degeneration and diabetic retinopathy, which are treated using anti-VEGF medications.

Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-vascular endothelial growth factor therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The anti-vascular endothelial growth factor therapeutics market consists of revenues earned by entities by providing lapatinib (tykerb), sorafenib (nexavar), sunitinib (sutent), axitinib, and pazopanib. The market value includes the value of related goods sold by the service provider or included within the service offering. The anti-vascular endothelial growth factor therapeutics market also includes sales of drugs, injectables, and therapy-related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-vascular endothelial growth factor therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-vascular endothelial growth factor therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-vascular endothelial growth factor therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Eylea; Lucentis; Beovu
• 2) By Disease: Macular Edema; Diabetic Retinopathy; Retinal Vein Occlusion; Age-related Macular Degeneration
• 3) By End Users: Hospitals; Clinics; Oncology Centers; Other End Users
• Subsegments:
• 1) By Eylea: Indications; Dosage Forms
• 2) By Lucentis: Indications; Dosage Forms
• 3) By Beovu: Indications; Dosage Forms
• Companies Mentioned: F. Hoffmann-La Roche AG; Biogen Inc.; Pfizer Inc.; Coherus BioSciences Inc.; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anti-Vascular Endothelial Growth Factor Therapeutics Market Characteristics

3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Trends And Strategies

4. Anti-Vascular Endothelial Growth Factor Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth Rate Analysis
• 5.4. Global Anti-Vascular Endothelial Growth Factor Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anti-Vascular Endothelial Growth Factor Therapeutics Total Addressable Market (TAM)

6. Anti-Vascular Endothelial Growth Factor Therapeutics Market Segmentation

• 6.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eylea
• Lucentis
• Beovu
• 6.2. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Age-related Macular Degeneration
• 6.3. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Oncology Centers
• Other End Users
• 6.4. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Eylea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Indications
• Dosage Forms
• 6.5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Lucentis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Indications
• Dosage Forms
• 6.6. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Beovu, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Indications
• Dosage Forms

7. Anti-Vascular Endothelial Growth Factor Therapeutics Market Regional And Country Analysis

• 7.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 8.1. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 9.1. China Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• 9.2. China Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 10.1. India Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 11.1. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• 11.2. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 12.1. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 13.1. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 14.1. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• 14.2. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 15.1. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• 15.2. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 16.1. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 17.1. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 18.1. France Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 19.1. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 20.1. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 21.1. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• 21.2. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 22.1. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 23.1. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• 23.2. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 24.1. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• 24.2. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 25.1. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• 25.2. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 26.1. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• 26.2. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 27.1. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 28.1. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• 28.2. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market

• 29.1. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
• 29.2. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Vascular Endothelial Growth Factor Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Anti-Vascular Endothelial Growth Factor Therapeutics Market Competitive Landscape
• 30.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Coherus BioSciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Vascular Endothelial Growth Factor Therapeutics Market Other Major And Innovative Companies

• 31.1. Bausch Health Companies Inc.
• 31.2. Viatris Inc.
• 31.3. Xbrane Biopharma AB
• 31.4. Bayer AG
• 31.5. Regeneron Pharmaceuticals Inc.
• 31.6. Genentech Inc
• 31.7. Allergan Inc.
• 31.8. Novartis AG
• 31.9. kyowa Kirin Co. Ltd.
• 31.10. Amgen Inc.
• 31.11. AstraZeneca plc
• 31.12. Merck & Co. Inc.
• 31.13. Johnson & Johnson Private Limited
• 31.14. Sanofi S.A.
• 31.15. AbbVie Inc.

32. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Vascular Endothelial Growth Factor Therapeutics Market

34. Recent Developments In The Anti-Vascular Endothelial Growth Factor Therapeutics Market

35. Anti-Vascular Endothelial Growth Factor Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Anti-Vascular Endothelial Growth Factor Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anti-Vascular Endothelial Growth Factor Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer